Core Viewpoint - The article discusses the financial and governance crisis faced by Clear Medical (01406.HK), a Hong Kong-listed ophthalmology service provider, following multiple trading suspensions and allegations of systematic fraud during its IPO process [1][2][9]. Group 1: Company Background and IPO - Clear Medical was considered a "star IPO" in 2022, raising HKD 218 million at an issue price of HKD 1.60 per share [2]. - The company claimed that its founders received a fixed salary of HKD 200,000 per month, which contributed significantly to its reported profits during the fiscal years 2019-2021 [2]. - However, it was revealed that the founders actually received performance-based variable compensation, with one founder's actual salary reaching HKD 12.61 million in the 2019 fiscal year, contradicting the IPO disclosures [2][3]. Group 2: Financial Performance Post-IPO - Following the termination of fixed salary contracts by the founders, Clear Medical's net profit plummeted to a loss of HKD 3.19 million in the 2023 fiscal year, down from a profit of HKD 13.49 million in 2022 [3]. - The company distributed HKD 148 million in dividends from 2019 to 2021, exceeding its total profits during that period by 40% [3]. Group 3: Allegations and Key Individuals - An anonymous email alleged that a key figure, Mok Tsan San, acted as an intermediary for "illegal IPO funds" and attempted to manipulate the new management team [4][5]. - Mok has a controversial history, having been involved in companies that faced significant stock price declines and eventual delistings [5]. - The article highlights ongoing concerns regarding the old management team, particularly regarding their influence and potential attempts to undermine the new management [7][8]. Group 4: Regulatory Actions and Market Implications - The Hong Kong Securities and Futures Commission is expected to investigate the allegations, which raises broader concerns about the integrity of the IPO process and corporate governance in the Hong Kong market [9]. - The article emphasizes the need for a shift towards transparent and responsible management to restore trust in the Hong Kong capital market [9].

中青宝财务造假案中案？恐涉高德信IPO欺诈发行 近日，中青宝发布公告称，因涉嫌2019年至2021年年度报告存在虚假记载，以及未及时披露实际控 制人被采取刑事强制措施，公司收到深圳证监局下发的《行政处罚事先告知书》。公司及实际控制人、 多名高管面临被给予警告并处以罚款的处罚，罚款金额合计1470万元。公司股票自3月18日起被实施其 他风险警示，股票简称变更为"ST中青宝（维权）"。 中青宝是否沦为高德信IPO欺诈的"白手套"？ 首先，中青宝的溃败，或暴露出家族式企业治理的致命缺陷： 实控人凌驾内控：李瑞杰家族长期掌控董事会与子公司运营。2023年12月实控人张云霞因债务纠纷 被刑拘后，李瑞杰要求公司隐匿信息长达7个月，直至2024年7月才披露，直接动机是为保障关联企业融 资不受影响。这种"个人利益优先"的决策模式，导致内控机制完全失效。 其次，公司信披违规"惯性化"： 收购空壳公司：2022年以溢价3倍收购实控人控制的宝德香港公司，但未披露其近乎空壳的实质， 被深交所认定信披不完整。 经查明，2019年至2021年期间，中青宝全资子公司深圳市宝腾互联科技有限公司与深圳市高德信通 信股份有限公司签订采购合同，后 ...

文/梧桐小新 3月14日，上交所披露三份纪律处分决定书，曾申报科创板IPO的安徽安芯电子科技股份有限公司因各项违规被予以1年内不接受其提交的发行上市申请文件的纪律 处分，时任董事长兼总经理汪良恩、时任财务总监方月琴被公开谴责。 国元证券被通报批评，保荐代表人马志涛、徐明被予以6个月内不接受保荐代表人签字 的发行上市申请文件及信息披露文件的纪律处分。 容诚会计师事务所被通报批评，签字会计师郁向军、万文娟被予以6个月内不接受其签字的发行上市申请文件 及信息披露文件的纪律处分。 | 关于对容诚会计师事务所（特殊普通合伙）及郁向军、万文娟予以纪律处分的决定 | 2025-03-14 | | --- | --- | | 关于对国元证券股份有限公司及马志涛、徐明予以纪律处分的决定 | 2025-03-14 | | 关于对安徽安芯电子科技股份有限公司及相关责任人予以纪律处分的决定 | 2025-03-14 | 安芯电子曾于2021年9月向上交所申请首次公开发行股票并在科创板上市，后于2023年9月撤回发行上市申请文件。在发行上市申请过程中，安芯电子对研发人 员、研发投入、营业收入等事项先后出具多份自查报告，承诺相关信息披露 ...